Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

Clinical trial NCT05555615 · TERMINATED

Trial details

NCT number: NCT05555615
Sponsor: ACADIA Pharmaceuticals Inc.
Status: TERMINATED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Irritability Associated With Autism Spectrum Disorder

Start date: 2022-11-02
Primary completion: 2025-02-14
Enrollment: 209

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.